PODD 8-K
Insulet Corp (PODD)
8-K
2025-10-23
For: 2025-10-21
View Original
Added on
April 08, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 21, 2025
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
| (Address of principal executive offices) | (Zip Code) | |||||||||||||
Registrant’s telephone number, including area code: | ||||||||||||||
| Not Applicable (Former name or former address, if changed since last report) | ||||||||||||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
| Emerging growth company | |||||
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐ | ||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. | ||||
On October 21, 2025, the Board of Directors (the "Board") of Insulet Corporation (the "Company") appointed Robbie Huffines as a Class II director, effective October 31, 2025. Mr. Huffines will stand for election by stockholders at the Company’s 2027 Annual Meeting of Stockholders. Mr. Huffines has been named to the Audit Committee of the Board, effective October 31, 2025.
Mr. Huffines was a Global Chair of Investment Banking and a member of the Executive Committee at JP Morgan Chase & Co. from 2020 until he retired in 2024. From 2011 to 2020, he was the company’s Vice Chair of Investment Banking and from 2002 to 2010, he was the co-head of the global healthcare investment banking group. Mr. Huffines began his career at JP Morgan Chase in 1992 in the mergers and acquisitions group, focusing on healthcare. Prior to joining J.P. Morgan Chase, Mr. Huffines worked at Alex Brown & Sons, specializing in equity financing and advisory assignments for emerging growth companies.
Mr. Huffines is the co-founder of The Forest Group, a nonprofit organization dedicated to improving the mental health of children in underserved communities. He is currently a member of the board of directors of the Hastings Center for Biomedical Ethics, an independent, nonpartisan bioethics research institute, of Eikon Therapeutics, Inc., a pivotal-stage biotechnology company that works to develop new medicines to address grievous illnesses, and of Nextech Invest Ltd., a cancer-focused venture capital firm headquartered in Zurich, Switzerland. He also served as a director of Walgreens Boots Alliance until its sale in August 2025. Mr. Huffines has an M.B.A. from the University of Virginia, where he received the Faculty Award for academic excellence. He has a B.A. from the University of North Carolina, where he majored in English and Economics.
There are no arrangements or understandings between Mr. Huffines and any other persons pursuant to which he was selected as a director. There are no transactions involving Mr. Huffines required to be disclosed under Item 404(a) of Regulation S-K. As a non-employee director of the Company, Mr. Huffines will receive cash and equity compensation pursuant to the Company's non-employee director compensation program, as described in the “Non-Employee Director Compensation” section of Company's proxy statement filed with the Securities and Exchange Commission on April 29, 2025, as may be adjusted by the Board from time to time.
| Item 7.01 | Regulation FD Disclosures. | ||||
On October 23, 2025, the Company issued a press release announcing the appointment of Mr. Huffines to the Board. A copy of that press release is furnished herewith as Exhibit 99.1.
| Item 9.01 | Financial Statements and Exhibits | ||||
| (d) | Exhibits. | |||||||
| Exhibit No. | Description | |||||||
Press Release dated October 23 2025 | ||||||||
| 104 | Cover Page Interactive Date File (formatted as Inline XBRL) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report to be signed on its behalf by the undersigned thereunto duly authorized.
| INSULET CORPORATION | |||||||||||||||||
| Date: October 23, 2025 | By: | /s/ John W. Kapples | |||||||||||||||
| John W. Kapples | |||||||||||||||||
| Senior Vice President and General Counsel | |||||||||||||||||
Exhibit 99.1
Insulet Announces Appointment of Robert L. Huffines to its Board of Directors
ACTON, Mass.— October 23, 2025 — (BUSINESS WIRE)— Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Robert (“Robbie”) L. Huffines, a former Global Chair of Investment Banking at JP Morgan Chase & Co., to the Company’s board of directors, effective October 31, 2025. Mr. Huffines joins the board as an independent director and will serve on the board’s Audit Committee.
“We are honored to welcome Robbie to Insulet’s Board of Directors,” said Timothy Scannell, Chairman of the Board. “Robbie brings more than three decades of distinguished experience advising healthcare companies at one of the world’s leading financial institutions. His strategic insight and deep industry knowledge will be instrumental as Insulet accelerates its growth and continues delivering sustainable value to our shareholders, communities, partners and the patients we serve.”
“I’m excited to join Insulet’s Board at such a pivotal time in the company’s journey,” said Robbie Huffines. “Insulet’s commitment to innovation and improving the lives of people with diabetes is deeply inspiring. I look forward to working alongside the Board and leadership team to help advance the company’s mission and drive long-term value for all stakeholders.”
About Robbie Huffines
Mr. Huffines joined J.P. Morgan in 1992 in the Mergers and Acquisitions group, with a focus on the healthcare industry. From 2002 to 2010, he served as co-head of the company’s global healthcare investment banking group, and, from 2011 to 2020, Mr. Huffines served as JP Morgan Chase’s Vice Chairman of Investment Banking. From 2020 to 2024, Mr. Huffines was the company’s Global Chair of Investment Banking and a member of the Executive Committee. Prior to joining J.P. Morgan, he worked at Alex Brown & Sons, specializing in equity financing and advisory assignments for emerging growth companies.
Mr. Huffines and his wife, Lisa Huffines, founded The Forest Group, Inc., a not-for-profit organization focused on improving the mental health of children in underserved communities. Mr. Huffines currently serves on the boards of directors of Nextech Invest Ltd., Eikon Therapeutics, and the Hastings Center for Biomedical Ethics. He also served as a director of Walgreens Boots Alliance until its sale in August 2025.
Mr. Huffines earned his M.B.A. from the Darden School of Business at the University of Virginia, where he received the Faculty Award for academic excellence. He pursued his baccalaureate education at the University of North Carolina, where he majored in English and Economics.
About Insulet Corporation
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit: Insulet.com or omnipod.com.
©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved.
Investor Relations:
Clare Trachtman
Vice President, Investor Relations
(978) 218-0889
Media:
Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
Source: Insulet Corporation